|
|
|
|
|
|
Sponsored by: |
Pfizer |
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00134511 |
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known disorder of extremely high cholesterol
Condition | Intervention | Phase |
Hypercholesterolemia, Familial |
Drug: Torcetrapib/atorvastatin |
Phase III |
MedlinePlus related topics: | Cholesterol |
ChemIDplus related topics: | Atorvastatin Atorvastatin calcium Cholest-5-en-3-ol (3beta)- Torcetrapib |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |||||
Pfizer Investigational Site | |||||
Boston, Massachusetts, United States, 02114 | |||||
Canada, Quebec | |||||
Pfizer Investigational Site | |||||
Chicoutimi, Quebec, Canada, G7H 5H6 | |||||
Pfizer Investigational Site | |||||
Ste-Foy, Quebec, Canada, G1V 4M6 | |||||
South Africa | |||||
Pfizer Investigational Site | |||||
Bloemfontein, South Africa, 9301 | |||||
Pfizer Investigational Site | |||||
Cape Town, South Africa, 7925 | |||||
South Africa, Johannesburg | |||||
Pfizer Investigational Site | |||||
Parktown, Johannesburg, South Africa, 2193 |
Pfizer |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Link to ClinicalStudyResults.org Posting: 
  |
Study ID Numbers: | A5091027 |
First Received: | August 22, 2005 |
Last Updated: | November 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00134511 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|